New Releases from NCBI BookshelfTalazoparib (Talzenna): Indication: Talazoparib in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: Reimbursement Recommendation [Internet].Talazoparib (Talzenna): Indication: Talazoparib in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Talzenna in combination with enzalutamide should be reimbursed by public drug plans for the […]
